Connect with us

Regen BioPharma Inc (OTCMKTS: RGBP) Breaking Out as Biotech Files Patent on Dendritic Cell Technologies to Augment Efficacy of Survivin mRNA Cancer Immunotherapeutic Vaccine

Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful reversal rocketing back into penny land on Friday up 46% on $1.6 million in dollar volume. RGBP…

Published

1 year ago

on

Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful reversal rocketing back into penny land on Friday up 46% on $1.6 million in dollar volume. RGBP has a massive following of shareholders, many of them international that are jumping on board and accumulating heavily now that RGBP has reversed. Several weeks ago, the Company announced the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine.  RGBP CEO Dr. David Koos stated: “We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches.  We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine.”  

Microcapdaily has been reporting on RGBP since early last year. The last time we covered the Company we stated among other things: “RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; notably in the July PR Dr. koos stated: “We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. Rumors are circulating that Dr. Koos has offers for either a B/O or potential joint ventures, licensing, partnerships, or a merger. He wants to get the best offer out there. Regen owns a valuable intellectual property portfolio including 8 issued patents and 13 published patent applications, these patents address enormous billion-dollar markets. RGBP has not seen the kind of volume and interest it showed on Friday in a long time and looks to be preparing to embark on something substantial here.  

Regen BioPharma, Inc. - HomeRegen BioPharma Inc (OTCMKTS: RGBP) is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.  

Regen owns a valuable intelectuable property portfolio including 8 issued patents and 13 published patent applications. Zander Therapeutics, Inc. (a company under common control) has been granted an exclusive license to develop and commercialize IP controlled by the Company for non-human veterinary therapeutic use. Regen has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize “Antigen specific mRNA cellular cancer vaccines” for the treatment of pancreatic cancer and KCL Therapeutics, Inc. has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize certain intellectual property for the treatment of colon cancer. 

The Company is led by CEO David Koos who has over 30 years of investment banking and venture capital experience.  He has a deep knowledge of startup businesses, public markers and SEC reporting companies.  Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.  Additionally, he has authored / co-authored numerous peer reviewed journal articles. Dr. Koos worked hard to get the filings up to date and get the Company compliant which has recently been completed with RGBP now “pink current”  

Earlier this year RGBP announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen’s existing siRNA (small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. mRNA is a single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to ribosomes (the cell’s protein-making machinery).    

Regen has filed an Investigational New Drug Application (IND#16928) for their drug termed tCellVax   with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development. Dyo Biotechnologies has been contracted to assist Regen with the development of the above-mentioned technology. 

To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

On July 26 RGBP announced the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine.  

In 2021 the Company was granted US patent # 11,090,332 on composition of matter of survivin modified-mRNA useful for teaching the immune system to kill cancer. In the current patent, specific types of dendritic cells, means of generating specialized dendritic cells, and the planned formulation that will enter clinical trials have been granted patent protection. 

Immunotherapy of cancer represents a very large market which is currently being led by the class of drugs called “checkpoint inhibitors” and “CAR-T” cells.  To date there is no mRNA immunotherapy available for treating cancer. This patent application protects the use of our patented survivin mRNA both as a stand-alone vaccine and as an immunotherapy. 

RGBP CEO Dr. David Koos stated: “We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches.  We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine.” 

For more on RGBP Subscribe Right Now!

Currently trading at a $55 million market valuation RGBP has 5,024,517,324 shares outstanding and a debt load that has caused significant dilution in the past. But RGBP is an exciting story developing in small caps, at current levels the selling pressure that decimated the share price from over $0.08 to half a penny is gone and buyers have stepped in and are accumulating heavily at current levels. RGBP is no stranger to big moves and has runner in its blood skyrocketing to $0.0819 not once but twice in the past year alone. Several weeks ago, the Company announced the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine.  RGBP CEO Dr. David Koos stated: “We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches.  We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine.” Rumors are circulating that Dr. Koos has offers for either a B/O or potential joint ventures, licensing, partnerships, or a merger. He wants to get the best offer out there. Regen owns a valuable intellectual property portfolio including 8 issued patents and 13 published patent applications, these patents address enormous billion-dollar markets. RGBP has not seen the kind of volume and interest it showed on Friday in a long time and looks to be preparing to embark on something substantial here. We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article

The post Regen BioPharma Inc (OTCMKTS: RGBP) Breaking Out as Biotech Files Patent on Dendritic Cell Technologies to Augment Efficacy of Survivin mRNA Cancer Immunotherapeutic Vaccine first appeared on Micro Cap Daily.

Read More

Related Topics:
Continue Reading

Uncategorized

The metaverse is real: Zuck’s ‘incredible’ photorealistic tech wows crypto twitter

Often roasted for his metaverse tech demos, Zuckerberg appears to have blown away internet users with his latest avatar tech.
While…

Published

23 mins ago

on

September 28, 2023

By

Often roasted for his metaverse tech demos, Zuckerberg appears to have blown away internet users with his latest avatar tech.

While critics have been busy writing eulogies for Meta’s metaverse dream over the last few years, Mark Zuckerberg’s latest demonstration of its photorealistic avatars shows it could be pretty far from dead after all.

Appearing on a Sept. 28 episode of the Lex Fridman podcast, Zuckerberg and the popular computer scientist engaged in a one-hour face-to-face conversation. Only, it wasn’t actually in person at all.

Instead, the entirety of Fridman and Zuckerberg’s conversation used photorealistic realistic avatars in the metaverse, facilitated through Meta’s Quest 3 headsets and noise-canceling headphones.

Observers often have fun ridiculing Meta for dumping billions of dollars into metaverse research only to seemingly produce cartoonish avatars and wonky-looking legs.

However, in this case, users on social media, including those from Crypto Twitter, seemed to be genuinely impressed by the sophistication of the technology.

“Ok the metaverse is officially real,” wrote pseudonymous account Gaut, a rare moment of seemingly genuine praise from a user typically known for his satirical and sarcastic takes on current events.

“9 minutes into Lex / Mark metaverse podcast I forgot I was watching avatars,” wrote coder Jelle Prins.

Fridman and Zuckerberg speaking as virtual avatars in the metaverse. Source: Lex Fridman Podcast.

Fridman alsoshared his impressions of the experience in real-time, noting how “close” Zuckerberg felt to him during the interview. Moments later, he explained how difficult it was to recognize that Zuckerberg’s avatar wasn’t his physical body.

“I’m already forgetting that you’re not real.”

The technology on display is the newest version of Codec Avatars. First revealed in 2019, Codec Avatars is one of Meta’s longest-running research projects which aims to create fully photorealistic real-time avatars that work by way of headsets with face tracking sensors.

Related: Meta refutes claims of copyright infringement in AI training

However, users may need to wait a few years before donning their own realistic avatars, said Zuckerberg, explaining that the tech used requires expensive machine learning software and full head scans by specialized equipment featuring more than 100 different cameras.

This would be, at the very least, three years away from being available to everyday consumers, he said.

Still, Zuckerberg noted that the company wants to reduce the barriers as much as possible, explaining that in the future, these scans may be achievable with a regular smartphone.

The most-recent demonstration comes just one day after Meta unveiled its answer to ChatGPT, revealing its newest AI assistant Meta AI, which is integrated across a range of unique chatbots, apps and even smart glasses.

AI Eye: Real uses for AI in crypto, Google’s GPT-4 rival, AI edge for bad employees

Read More

Continue Reading

Uncategorized

New Tables Show Intermediate-Term Overview is Negative

We have introduced two new tables in the DecisionPoint ALERT to give an overview of trend and BIAS for the major market indexes, sectors, and industry…

Published

24 mins ago

on

September 28, 2023

By

We have introduced two new tables in the DecisionPoint ALERT to give an overview of trend and BIAS for the major market indexes, sectors, and industry groups that we track. The first is our Market Scoreboard, which shows the current Intermediate-Term and Long-Term Trend Model (ITTM and LTTM) signal status. To review:

  • The IT Trend Model generates a BUY Signal when the 20-day EMA crosses up through the 50-day EMA (Silver Cross).
  • The IT Trend Model generates a NEUTRAL Signal when the 20-day EMA crosses down through the 50-day EMA (Dark Cross) above the 200-day EMA. This is a soft SELL Signal, going to cash or a hedge. It avoids being short in a bull market.
  • The IT Trend Model generates a SELL Signal when the 20-day EMA crosses down through the 50-day EMA (Dark Cross) below the 200-day EMA.
  • The LT Trend Model generates a BUY Signal when the 50-day EMA crosses up through the 200-day EMA (Golden Cross).
  • The LT Trend Model generates a SELL Signal when the 50-day EMA crosses down through the 200-day EMA (Death Cross).

The current table shows that there is considerable stress in the intermediate-term; however, the long-term is still comfortably green for market and sector indexes. But we need to remember that the market indexes are cap-weighted, which means that they can be held aloft by large-cap stocks. The 11 sectors shown are composed solely of S&P 500 components, meaning that they will reflect the strength of that index. Industry groups, however, are not doing as well because they are less protected by the large-cap umbrella.

Next, let's look at how we determine the BIAS of a given index. First, the Silver Cross Index shows the percentage of stocks in an index that have a Silver Cross (20-day EMA above the 50-day EMA), and the Golden Cross Index shows the percentage of stocks in the index that have a Golden Cross (50-day EMA above the 200-day EMA). Next, we determine BIAS based upon the relationship of the Silver Cross Index to its 10-day EMA and the relationship of the Golden Cross Index to its 20-day EMA. When they are above, the BIAS is bullish. When they are below, the BIAS is bearish. See the chart below.

The following table shows the current intermediate-term and long-term BIAS of the market, sector, and industry group indexes we follow. Note that the picture is extremely bearish, but it is a very oversold condition, which will shift toward the positive in the event of a strong rally.

Conclusion: These new tables, available daily in the DecisionPoint ALERT, provide a quick overview of market trend and BIAS. They are intended to help focus attention on areas that may be of interest. They do not give action commands, but provide information flags to prompt assessment of the relevant charts.

Learn more about DecisionPoint.com:

Watch the latest episode of DecisionPoint on StockCharts TV's YouTube channel here!

Try us out for two weeks with a trial subscription!

Use coupon code: DPTRIAL2 at checkout!

Technical Analysis is a windsock, not a crystal ball. --Carl Swenlin

(c) Copyright 2023 DecisionPoint.com

Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional. Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.

DecisionPoint is not a registered investment advisor. Investment and trading decisions are solely your responsibility. DecisionPoint newsletters, blogs or website materials should NOT be interpreted as a recommendation or solicitation to buy or sell any security or to take any specific action.

Helpful DecisionPoint Links:

DecisionPoint Alert Chart List

DecisionPoint Golden Cross/Silver Cross Index Chart List

DecisionPoint Sector Chart List

DecisionPoint Chart Gallery

Trend Models

Price Momentum Oscillator (PMO)

On Balance Volume

Swenlin Trading Oscillators (STO-B and STO-V)

ITBM and ITVM

SCTR Ranking

Bear Market Rules

Read More

Continue Reading

International

Tesla rival Polestar reveals lineup of its new electric vehicles

The Sweden-based electric vehicle maker completes key testing before launching production of its new SUV.

Published

25 mins ago

on

September 28, 2023

By

Tesla's Model Y crossover, the best-selling vehicle globally, is the standard that electric vehicle makers strive to compete with. The Austin, Texas, automaker sold about 267,200 Model Y vehicles in the first three months of the year and continued leading the pack well into the second quarter.

It's no wonder that the Model Y is leading all vehicles in sales as it retails for about $39,390 after tax credits and estimated gas savings. Ford  (F) - Get Free Report hopes to compete with the Model Y about a year from now when it rolls out the new Ford Explorer SUV that is expected to start at $49,150.

Related: Honda unveils surprising electric vehicles to compete with Tesla

Plenty of competition in electric SUV space

Mercedes-Benz (MBG) however, has a Tesla rival model with its EQB all-electric compact sports utility vehicle with an estimated 245 mile range on a charge with 70.5 kWh battery capacity, 0-60 mph acceleration in 8 seconds and the lowest price of its EVs at a $52,750 manufacturers suggested retail price.

Tesla's Model X SUV has a starting price of about $88,490, while the Model X full-size SUV starts at $98,490 with a range of 348 miles. BMW's  (BMWYY) - Get Free Report xDrive50 SUV has a starting price of about $87,000, a range up to 311 miles and accelerates 0-60 miles per hour in 4.4 seconds.

Polestar  (PSNY) - Get Free Report plans to have a lineup of five EVs by 2026. The latest model that will begin production in the first quarter of 2024 is the Polestar 3 electric SUV, which is completing its development. The vehicle just finished two weeks of testing in extreme hot weather of up to 122 degrees in the desert of the United Arab Emirates to fine tune its climate system. The testing was completed in urban cities and the deserts around Dubai and Abu Dhabi.

“The Polestar 3 development and testing program is progressing well, and I expect production to start in Q1 2024. Polestar 3 is at the start of its journey and customers can now visit our retail locations around the world to see its great proportions and sit in its exclusive and innovative interior,” Polestar CEO Thomas Ingenlath said in a statement.

Polestar 3 prototype is set for production in the first quarter of 2024.

Polestar

Polestar plans 4 new electric vehicles

Polestar 3, which will compete with Tesla's Model X, Model Y, BMW's iX xDrive50 and Mercedes-Benz, has a starting manufacturer's suggested retail price of $83,000, a range up to 300 miles and a charging time of 30 minutes. The company has further plans for the Polestar 4, an SUV coupé that will launch in phases in late 2023 and 2024, as well as a Polestar 5 electric four-door GT and a Polestar 6 electric roadster that the company says "are coming soon." 

The Swedish automaker's lone all-electric model on the market today is the Polestar 2 fastback, which has a manufacturer's suggested retail price of $49,900, a range up to 320 miles and a charging time of 28 minutes. The vehicle accelerates from 0-60 miles per hour in 4.1 seconds. Polestar 2 was unveiled in 2019 and delivered in Europe in July 2020 and the U.S. in December 2020.

Polestar 1, the company's first vehicle, was a plug-in hybrid that went into production in 2019 and was discontinued in late 2021, according to the Polestar website.

The Gothenburg, Sweden, company was established in 1996 and was sold to Geely affiliate Volvo in 2015.

Get the smart plays to grow your portfolio. Join TheStreet® | SMARTS and take $10 OFF the original price!

Read More

Continue Reading

Trending